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We have determined the sequence of the human immunodeficiency virus type 1 (HIV-1) vif genes from a cohort of 42
long-term nonprogressors (LTNP) and compared these sequences to those of 8 late progressors. The coding potential of the
vif open reading frame directly derived by nested PCR from uncultured peripheral blood mononuclear cell DNA was
conserved in all 50 individuals. The nucleotide distances between vif sequences were not significantly different between
LTNP and late progressors, indicating similar selections of viruses within both types of long-term HIV-1-infected subjects.
However, a statistically significant correlation between an amino acid signature at position 132 of Vif and the viral load was
found within LTNP. Namely, amino acid Ser was associated with low viral load and amino acid Arg with high viral load. This
signature was also observed when LTNP with low viral load were compared to progressors. The Ser132 signature was
introduced in place of Arg132 present in the HIV-1 YU-2 Vif prototype into chimeric viruses to assess the impact of Vif
signature on the virus. While the replication properties in the SupT1 cell line were unmodified, the mutagenized virus revealed
a fivefold decreased replication in activated PBMC, suggesting a possible role of this Vif signature for viral production in vivo.
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INTRODUCTION
Five to ten percent of human immunodeficiency virus
type 1 (HIV-1)-infected individuals remain asymptomatic
without anti-retrovirus therapy for more than 10 years
and present stable levels of peripheral blood CD4-posi-
tive cells greater than 500 per mm3. The long-term non-
progressors (LTNP) identified in several studies (Buch-
binder et al., 1994; Cao et al., 1995; Learmont et al., 1992;
ifson et al., 1991; Sheppard et al., 1993) can constitute a
istinct group which may not develop AIDS or can cor-
espond to the slowest progressors among the normal
istribution of HIV-1-infected individuals.
Initial studies on viruses isolated from LTNP have
evealed defects in nef (Deacon et al., 1995; Kirchhoff et
l., 1995; Mariani et al., 1996; Premkumar et al., 1996), in
ev (Iversen et al., 1995), in vpr, vif, and vpu (Michael et
l., 1995a; Wang et al., 1996), and in env (Connor et al.,
996) genes, suggesting that those individuals may be
nfected by attenuated viruses. More recent compilations
f nucleotide sequences of gag-pol, vif, vpr, vpu, env, nef,
nd LTR of HIV-1 from 10 LTNP failed to confirm the
1 See appendix for members.
2 To whom correspondence and reprint requests should be ad-
dressed at INSERM Unit U372, Pathoge´nie des infections a` lentivirus,
t
L
BP 178, 13276 Marseille cedex 9, France. Fax: 33 04 91 82 60 61. E-mail:
rvigne@inserm-u372.univ-mrs.fr.
169resence of defective genes and revealed overall intact
IV-1 genes within these individuals (Connor et al., 1996;
uang et al., 1995a,b, 1998; Zhang et al., 1997a,b). More-
ver, they did not find any clearcut correlation between
he genotypes and the disease status, which was con-
irmed in the extensive study on the structure and func-
ion of nef within another cohort by Michael et al. (1995b).
owever, all of these studies have analyzed a limited
umber of individuals and have not assessed the possi-
le relation between viral nucleotide sequences and the
lasma viral load.
We report here our results on vif gene sequences from
2 LTNP untreated with anti-retroviral therapy (referred to
ere as the ALT cohort; (Candotti et al., 1999). This
uxiliary gene is required for HIV-1 replication in primary
ymphocytes and macrophages (Chowdhury et al., 1996;
isher et al., 1987; Gabuzda et al., 1992, 1994; Sakai et al.,
988; Sova and Volsky, 1993; von Schwedler et al., 1993)
nd consequently is largely maintained intact in vivo in
dults (Sova et al., 1995; Wieland et al., 1994; Zhang et al.,
997a) and in perinatally infected infants (Yedavalli et al.,
998). Our goal was to determine whether defined amino
cid residues at particular positions of the predicted vif
ene product were related to the viral load parameter
mong LTNP individuals. We found a statistically signif-
cant correlation between one precise amino acid signa-
ure at position 132 of Vif and the viral load within the
TNP. This signature was also observed when LTNP with
0042-6822/00 $35.00
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Ser132 in place of Arg132 present in HIV-1 YU-2 Vif
prototype was introduced into a chimeric virus to assess
the impact of the Vif signature on the replication proper-
ties of HIV-1 in activated peripheral blood mononuclear
cells (PBMC), the mutagenized virus revealed a fivefold
reduced replication, suggesting a possible role of this Vif
signature for virus production in vivo.
RESULTS
Definition of the asymptomatic subjects
The group of LTNP in this study consisted of 42 sub-
jects HIV-1 infected since at least 8 years with stable
CD4 cell counts (no significant decline of this count in
the past 3 years). In parallel, 8 HIV-1-positive subjects
with similar duration of HIV-1 infection but exhibiting
significant declines of CD4 cell count in the past 3 years
(decline of at least 25% during this period) were used as
late progressor controls. Viral loads and CD4 cell counts
of all subjects were determined within the first year after
inclusion in the cohort. According to the viral load pa-
rameters (Table 1), the 42 LTNP were divided into two
groups, 18 low viral load (LVL) LTNP and 24 high viral
load (HVL) LTNP. LVL LTNP individuals presented viral
loads inferior or equal to 10,000 copies/ml and HVL LTNP
shared viral loads greater than 10,000 copies/ml. Viral
load means corresponded to 2273, 189,858, and 305,850
RNA copies/ml within the three respective groups, LVL
LTNP, HVL LTNP, and late progressors. CD4 T-cell count
means were similar in both LVL and HVL groups (728
and 637). The late progressor group presented a lower
CD4 T-cell count mean equal to 265.
vif sequence data obtained and deduced Vif proteins
TABLE 1
Clinical Characteristics of LVL and HVL LTNP and of the
Eight Late Progressors
Viral load and CD4
counts
LVL LTNP
(n 5 18)
HVL LTNP
(n 5 24)
Late
progressors
(n 5 8)
lasma viral load mean
(RNA copies/ml) 2273 189,858 305,850
ange 20–7800 11,000–860,000 2200–1,860,000
lood CD4 cell number
(cells/ml) 728 637 265
Range 434–1210 278–1153 158–354
Note. Plasma viral loads (RNA copies per milliliter) and absolute CD4
T cell counts (cells per microliter) were measured within 1 year after
enrollment, as described by Candotti et al. (1999). No anti-retroviral
therapy was prescribed before this first cross sectional survey. Mean
and range of values were calculated for the three groups of individuals.
170 HASSAProviral DNA as well as viral RNA was purified, re-
spectively, from PBMC and from plasma viral particles.Nested Pfu PCR or RT-PCR allowed us to obtain a DNA
fragment corresponding to the vif open reading frame
(576 nt). The DNA fragments were directly sequenced.
The majority of vif sequences were obtained from PBMC
proviral DNA (denominated A1) and a few from plasma
viral RNA (denominated B1). All sequences except one
were taken from individuals within the first year after
inclusion into the cohort. One single HVL LTNP PBMC
sample vi04048A2H was taken within the second year
after inclusion. Three LVL vif sequences, vi06002C1L,
vi04005C1L, and vi11007C1L, were derived from PBMC
cocultures, the only way to successfully amplify the pro-
viral sequences. Figure 1 shows the alignment of Vif
amino acid sequences deduced from the nucleotide se-
quences. In addition to the Vif sequences from the eight
control progressors of our cohort, seven Vif sequences,
which were obtained by amplification of PBMC DNA from
AIDS patients and were published by Sova et al. (1995),
were also aligned (Vif GMK1 to 4, VifGMK6 to 8). The
major amino acid sequence of all subjects was found to
be full-length, i.e., 192 amino acids long except for one
subject (11007) who presents a Vif protein with 193
amino acids with an additional D at position 62.
As observed previously by various authors, different
discrete regions, amino acids 27–52, 60–67, 92–102, 120–
137, and 151–167, were particularly variable. Between
these regions, conserved motifs were observed, in par-
ticular the SLQXLA motif located between amino acids
144 and 149 (Oberste and Gonda, 1992) and two other
motifs in the last 30 C-terminal amino acids of the Vif
protein, i.e., 161PPLPS165 and 168KLTEDRWN175. These two
latter motifs are located in the domain which is in asso-
ciation with the plasma membrane and with the Gag-
precursor (Bouyac et al., 1997; Goncalves et al., 1995).
Moreover Arg and Lys residues within the C-terminal end
of Vif (8 to 11 residues between the positions 157 and
192), which are the most important residues for those
interactions, are largely conserved in all LTNP as well as
in late progressor Vif sequences. All LTNP sequences
contain Ser144 and Thr188, which are the sites of serine
hreonine protein kinases (Yang et al., 1996), as well as
hr96 and Ser165, which are the sites of the MAP kinase
(Yang and Gabuzda, 1998). Last, both cysteine residues
which have been shown to be critical for the Vif function
(Ma et al., 1994) were conserved in all Vif proteins.
Phylogenetic relationship of vif sequences and
genetic diversity
Figure 2 shows the dendogram, drawn by the neighbor
joining method, of all vif sequences, with the YU-2 vif
sequence as outgroup. Nucleotide sequences from the
LTNP subjects interdigitated with those of progressors
and AIDS patients without apparent strong grouping
T AL.among themselves. Moreover, the LTNP subjects were
analyzed in relation to their virus load and no clear
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171vif GENE OF LONG-TERM NONPROGRESSORS
s uence
¨subclusters were revealed within LVL and HVL LTNP.
Of note, sequence analysis of the envelope C2V3 do-
main revealed that all subjects who were currently
analyzed (i.e., 34 LTNP 1 6 progressors) were infected
by B subtype viruses (D. Candotti, personal communi-
cation) and, consequently, the variability of vif gene
FIG. 2. Phylogenetic tree of vif sequences from LTNP and late prog
oftware. The sequences are labeled as in Fig. 1. The outgroup seq
boostrapping values are indicated.
172 HASSAcould not be related, in our study, to differences in
HIV-1 clades.Comparative analysis of amino acid signature
patterns between LVL and HVL LTNP and between
LTNP and progressors
To investigate whether specific amino acids in Vif are
associated with different statuses of infected individuals
s. The tree of nucleotide sequences was constructed using ClustalW
was the reference HIV-1 YU-2 sequence (Li et al., 1992). Significant
T AL.ressor
INE E(LVL, HVL LTNPs, and progressors), the amino acid sig-
nature pattern in the Vif amino acid sequences was
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ccarefully analyzed within the different groups of individ-
uals (Table 2). The consensus Vif sequences from nine
long-term survivors (LTNP), described in the study of
Zhang et al. (1997b) and corresponding to LTNP with low
viral load, were also grouped and compared to se-
quences of progressors. The sequence comparisons
were performed with the VESPA algorithm (Korber and
Myers, 1992) and tested for their statistical significance
by the x2 test.
Six amino acid positions were revealed when Vif se-
uences were compared in different ways as shown in
able 2. The most statistically significant signatures
ere restricted to positions 132 and 159. More precisely,
mino acid S at position 132 was correlated with the LVL
TNP status, and alternative R residue was associated
ith the HVL LTNP and progressor status. The I residue
f the position 159 was predominant within the LVL
TNP, the LTNP of Zhang’s study, and within overall LTNP
equences while the T residue marked the progressor
equences. However, the residue at position 159 did not
T
Signature Pattern Analysis of
Number of samples with th
amino acid sequ
Subject group comparisonb
33 63
R G R K K
LVL LTNP 4 9 9
VL LTNP 9 8 8
TNP 27 12
rogressors 5 7
VL LTNP 13 3 9
Progressors 5 7 4
HVL LTNP 9 8 14 9
rogressors 4 8 5 7
hang LTNP
rogessors
VL LTNP 1 Zhang LTNP 17 8 13
rogessors 5 7 4
ll LTNP 31 17
rogessors 5 7
a The amino acid signatures relative to different subject group comp
ested for their statistical significance by x2 test using Statview (Abacu
0.05 in the x2 test. Open squares indicate comparison pairs, which giv
alues less than 0.05, for both compared residues versus other resid
onsidered a significant signature for a subject group.
b Zhang LTNP correspond to nine LTNP described by Zhang et al. (199
and to seven AIDS progressors from Sova et al. (1995) (see Fig. 1).
nP
nP
NP
vif GENE OF LONG-istinguish the LVL from HVL sequences. In conclusion,
mino acid S at position 132 was associated with LTNP
a
if low viral load and R at the same position was asso-
iated with LTNP of high viral load and with progressor
ndividuals. In contrast, amino acids I and T at position
59 were associated with nonprogressors and progres-
ors, respectively, independently of the viral load param-
ter.
orrelation between viral load in LTNP individuals
nd amino acid signature at position 132
The statistical significance of the amino acid signa-
ure at position 132 was further assessed by estimat-
ng a possible correlation between measured viral
oads of each LTNP individual (not shown in Table 1)
nd the signatures of position 132 by Mann–Whitney
nd Kruskall–Wallis testing. We confirmed that the
ignatures S and R at position 132 are highly associ-
ted with the viral load parameter within LTNP indi-
iduals (S with low viral load, R with high load), while
he other signatures, including I and T of position 159,
d HVL LTNP and Progressors
ated residues at six critical positions of Vif
cording to the group of subjects
101 132 159
Number of
subjectsD N S R I T
10 7 18
6 18 24
17 14 27 6 42
4 6 5 6 15
7 5 10 7 14 1 18
4 6 3 12 5 6 15
14 9 7 5 24
4 6 5 6 15
6 2 7 1 9
3 12 5 6 15
16 9 21 2 27
3 12 5 6 15
34 7 51
5 6 15
s were determined by VESPA software (Korber and Myers, 1992) and
epts). Closed squares indicate pairs with probability values less than
ability values comprised between 0.05 and 0.08. When x2 test gives P
one position (for example, S and R at position 132), the position is
ogressors correspond to the eight late progressors of the present study
nP nP
nP nP
nP nP nP nP
nP nP nP
nP nP nP
nP nP
nP
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TERMre not (Table 3). The mean viral load for the 16 LTNP
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I¨NE E21,536, while the mean viral load for the 25 individuals
containing R was 159,287 6 44,590 with a good sta-
istical significance using the Mann–Whitney test (P 5
.018) (when the single individual with residue Q at
osition 132 was excluded) and the Kruskall–Wallis
est (P 5 0.05) when the individual with Q was main-
ained. In contrast, as expected, no correlation was
easured for all other positions.
Moreover, any important bias regarding the nature of
he source material for amplification, i.e., PBMC DNA or
lasma RNA, has been excluded. Indeed, a comparative
nalysis of S and R signatures in the Vif proteins de-
uced from both source materials of 10 individuals re-
ealed that 8 patients had unchanged signatures (6 with
and 2 with S) while only 2 patients had distinct signa-
ures with an S in PBMC DNA and an R in plasma RNA
data not shown).
We could therefore conclude that the signature at
osition 132 is significantly correlated to the viral load in
LTNP environment and that the S signature may confer
TABLE 3
Correlation between Viral Loads within LTNP Individuals and Amino
Acid Signatures at Position 132
Vif signature within
individuals LTNP
Number of
individuals
Mean viral load 6
standard errora
Position 33 G 17 113,376 6 47,907
R 13 61,397 6 27,168
K 11 169,995 6 76,102
E 1 2000
Position 63 R 27 83,258 6 28,147
K 12 123,461 6 47,354
T 1 210
E 1 7800
S 1 860,000
Position 92 R 18 93,070 6 47,306
K 17 96,032 6 37,645
E 6 214,933 6 100,396
D 115
Position 101 D 17 148,286 6 59,397
N 14 86,032 6 42,028
G 6 43,363 6 35,642
E 2 170,045 6 169,955
A 1 115
V 1 110,000
S 1 162,000
Position 132 S 16 38,096 6 1536
R 25 159,287 6 44,590
Q 1 5,800
Position 159 I 27 110,577 6 40,410
T 6 89,952 6 54,162
R 9 119,135 6 55,410
a Statistical data were obtained with Mann–Whitney and Kruskall–
Wallis tests. Square symbols indicate the S/R pair comparison which
was statistically significant using the Mann–Whitney test (P , 0.05).
n
174 HASSAn attenuation of replication rather than a complete de-
ectiveness in PBMC. aunctional assay of the amino acid signatures S and
of position 132 of the YU-2 Vif protein
To address the role of this signature in the replication
roperties of HIV-1, chimeric viruses containing the res-
dues S or R at position 132 of an appropriate vif gene
roduct were constructed. The parental provirus corre-
ponded to a vif minus genome of HIV-1 NDK strain and
he inserted vif gene of subtype B HIV-1 was that of YU2
IV-1, where R at position 132 was mutated into S. After
ransfection of 293 cells, the reconstructed viruses were
rown in SupT1 cells permissive for both vif minus and
lus viruses. The replication properties of both recon-
tructed viruses in these permissive cells were identical
epending only on infectious dose and not on cloned vif
ene (data not shown). The virus stocks were titrated on
8166 cells and viruses were then assayed in PBMC
estrictive for vif minus viruses at two multiplicities of
nfection (m.o.i.) of 0.05 and 0.01 TCID/cell correspond-
ng, respectively, to 7.5 and 1.5 3 104 TCID/1.5 3 106 cells.
irus production was monitored twice a week by mea-
uring RT activity in infected cell culture supernatants
Fig. 3). Production of virus expressing 132S-mutated
U-2 Vif protein was reproducibly lower than that of
orresponding virus expressing R132 YU-2 Vif protein in
riplicate parallel infected cell cultures repeated three
imes with a mean ratio of 5.1 6 0.5 in restrictive PBMC
t day 8 postinfection. The average fivefold decrease in
iral production was correlated to a decrease in infectiv-
ty by measuring on C8166 the infectivity present in the
upernatants of PBMC at day 8 postinfection, after nor-
alization for the reverse transcriptase activity. The
ean ratio of normalized infectivities between R132 and
132 viruses grown in PBMC was 12.5 6 2.5 based on
riplicate parallel assays and on three different experi-
ents. Using a similar approach we constructed NDK
roviruses with nonmutated or mutated vif genes at po-
ition 159 from YU-2 with the mutation T159I. In replica-
ion assays of reconstructed viruses in PBMC, we could
ot observe any attenuating effect of the mutation T159I
data not shown). These different data allowed us to
onclude that serine at position 132 of Vif plays a critical
ole in the decreased replication of Vif S132-containing
iruses in restrictive PBMC.
DISCUSSION
A cross sectional analysis of HIV-1 vif sequences di-
ectly derived from the DNA of uncultured PBMC of 42
TNP and 8 late progressors revealed a very high fre-
uency of conserved intact open reading frames of the
if gene. By this approach, we analyzed the sequences of
if gene present in vivo without possible adaptation on in
itro cultivation. The two cysteines at position 114 and
33 (Ma et al., 1994), the phosphorylation sites on Ser144
T AL.and Thr188 by serine-threonine kinases (Yang et al., 1996)
nd on Thr96 and Ser165 by MAP kinase (Yang and
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TERMGabuzda, 1998), the series of Arg and Lys residues, and
a motif 161PPLP164 located in the C-terminus are well
onserved in all isolates, confirming their importance in
he function of Vif in vivo. Our results are consistent with
he earlier published analysis of vif sequences from
verall HIV-1-infected individuals (Sova et al., 1995; Wie-
FIG. 3. Replication kinetics of chimera HIV-1 derived from full-length
molecular clone HIV-1 NDK containing the vif gene of YU-2, wild type or
R to S mutated at position 132, in PHA/IL2-stimulated PBMC. Viruses
were prepared by transfecting HeLa cells with appropriate plasmids
and by passaging (13) virus contained in collected supernatants from
transfected HeLa cells in permissive SupT1 cells. Resulting virus
stocks were titrated in C8166 cells. PBMC cells (1.5 3 106) were
infected in triplicate with 1 ml containing 7.5 3 104 and 1.5 3 104 TCID
n parallel cultures (m.o.i. of 0.05 and 0.01). Virus replication was
ollowed by RT activity measurement in cell-free supernatant twice
eekly for 24 days. Data are expressed as mean values with standard
rrors of RT activities along triplicate parallel infections. Closed and
pen circles represent, respectively, nonmutated and mutated
R132S)YU-2 vif gene recombinant NDK viruses. Data represent
eans 6 standard errors of three parallel cultures determined in one
xperiment.
vif GENE OF LONG-and et al., 1994) as well as from LTNP (Zhang et al.,
997b).
1
lA significant correlation between plasma viral load
ithin LTNP individuals and one particular amino acid
ignature in Vif sequences was determined in the
resent study. This finding was possible because for the
irst time a significant number of LTNP has been studied
n the same cross sectional study. At position 132 of Vif,
er is related to low viral load, while Arg is more related
o high viral load. This signature can also distinguish
TNP with low viral load from progressors. That this
ignature was related at once to the viral load and to the
rogression status is not surprising since it is well
nown that the plasma viral load within infected individ-
als is significantly associated with progression rate
oward AIDS (Connor et al., 1993; Coombs et al., 1989;
ogervorst et al., 1995; Mellors et al., 1997; O’Brien et al.,
996; Piatak et al., 1993; Saag et al., 1991; Schnittman et
l., 1990). Last, it is interesting to note that the signifi-
ance of this signature might be restricted to the vif gene
f B clade HIV-1. Indeed, a previous report of Wieland et
l. (1997), identifying the sequences of vif genes of A and
clades of HIV-1 individuals of Uganda, did not point out
particular association between virus load and this Ser
ignature in Vif present in a large majority of A subtype
solates. However, in this study, the most relevant viral
oads from individuals infected by subtype A HIV-1 were
ot measured, and therefore no clearcut conclusion
ight be possible.
The in vivo importance of Vif position 132 on the viral
oad parameter was confirmed in vitro. A reconstructed
rovirus encoding Vif with S in position 132 was less
eplicative in PBMC (restrictive cells for the vif- viruses)
hile the replication in SupT1 (permissive cells) was
naltered. A 5-fold reduction of virus replication in PBMC
onfirmed by a 10-fold decrease in infectivity of viruses
ormalized for the reverse transcriptase activity is in
greement with the mean decrease in viral loads within
TNP containing S or R at position 132 (4-fold decrease
n copies per milliliter in plasma, see Table 3). It should
ave been important to control for the fact that primary
solates containing S132 replicate better than R132 vi-
uses but most of the S132 containing viruses were not
uccessfully isolated. Similarly, tentative cloning of com-
lete primary vif genes did not allow us to go further in
his approach as the vif genes from individuals with low
iral load were not easily amplified and, the obtained
equences being genetically heterogeneous, a high
umber of clones for each individual would be necessary
o compile conclusive data.
The functional role of position 132 of Vif is not known.
owever, it is interesting to note that residue 132 is just
pstream of the second cysteine 133, which is essential
or the infectivity of HIV-1 (Ma et al., 1994). Since it has
een shown that both Vif cysteine residues are not
inked by an intramolecular disulfide bond (Sova et al.,
175NONPROGRESSORS997), the residue at position 132 may contribute to a
ocal domain of Vif around cysteine 133 rather than to a
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Although this residue at position 132 may be important
for the optimal activity of Vif, the change in S to R at
position 132 may be compensated by changes at other
positions within Vif or by changes within other viral
proteins. This compensatory effect may explain that the
correlation which is observed in vivo between the signa-
ture at position 132 and the viral load is statistically
significant, but that exceptions to this association do
occur. Despite these restrictions, it is interesting to note
that among the nine LTNP patients studied by Zhang et
al. (1997b), six have the Ser residue and one has the
homologous Thr residue at position 132.
Moreover, in a longitudinal study of mother-to-child
transmission of HIV-1, Yedavalli et al. (1998) have char-
acterized the vif sequences of six pairs of infant and
mother and, interestingly, both pairs with asymptomatic
mother and infant had a large majority of genotypes
which code for Vif proteins with the S residue at position
132. These genotypes with S in position 132 are present
in the mother and in the infant after perinatal transmis-
sion. It appears that there is no selective pressure to
revert S into R, which, however, should easily occur since
S and R codons differ by a single third base. Therefore,
viruses with S132 are efficiently transmitted and well
adapted to their host and the appearance of S at position
132 might rather occur at random. Once obtained, this
residue is well conserved and may render the virus more
adapted to immunocompetent individuals, moderately
reducing its production.
Another mechanism related to the viral interference
may be possible. Indeed the S variant may interfere with
the R variant and therefore limits the outgrowth of the
rapid variant. This interference mechanism has already
been observed with a particular vif gene isolated from a
patient infected by HIV-1 which inhibits in trans HIV-1
wild-type viruses in either permissive or nonpermissive
cells (D’Aloja et al., 1998). Interestingly, this variant vif
gene contains several contiguous changes just up-
stream of the second conserved C residue at position
133, including the residue S132. Coinfection experiments
with both variants containing S or R at position 132 and
analysis of the resulting competition of both variants may
allow this second mechanism to be assessed.
In this study, we have revealed that the Vif protein
mutations may be subtly involved in the adaptation of
viral replication within immunocompetent LTNP. This ge-
netic determinant must be added to others, which were
previously described as being involved in governing the
rate of disease progression of HIV-1-infected patients.
Among them, the polymorphism of the CCR5 second
receptor is a good example showing that the relatively
frequent heterozygous profile (1/D32) CCR5 among in-
fected individuals from western Europe is a factor influ-
176 HASSAencing the rate of disease progression (Balfe et al., 1998;
Dean et al., 1996; Huang et al., 1996; Michael et al., 1997).
i
in our cohort, no direct correlation was observed be-
ween (1/D32) CCR5 heterozygosity and viral load pa-
ameters. This result is in agreement with a previous
tudy of Cohen et al. (1997), which found that CCR5
eterozygosity is not the sole determinant for the immu-
ologic and virologic phenotype of LTNP. Nevertheless,
hen combined genotypes of CCR5, CCR2, SDF1, and
LA genes were integrated in a statistical regression
odel, LTNP individuals could be significantly distin-
uished from progressors (Magierowska et al., 1999).
he recent discovery of a positive link between the
X3CR1 I249 M280 homozygosity and the more rapid
rogression to AIDS is another example of genetic risk
actor in HIV/AIDS, confirming that the rate of disease
ppearance is dependent on multiple factors (Faure et
l., 2000).
It is noteworthy that a correlation was observed be-
ween an E to D change at position 25 of the V3 loop of
he envelope glycoprotein and the viral load, with E
ssociated with low viral load and D with high viral load
Candotti et al., unpublished data). This last signature in
3 was previously observed in another study of 44 indi-
iduals classified as nonprogressors and slow progres-
ors, with the D residue at position 25 of V3 associated
ith the increased rate of disease progression (Balfe et
l., 1998).
Grossly defective nef gene sequences have also been
ssociated with LTNP status (Deacon et al., 1995; Kirch-
off et al., 1995; Salvi et al., 1998). In our study, prelimi-
ary data on nef sequences reveal a high frequency of
ull-length nef, excluding the possibility that the deletions
ithin nef contribute strongly to the LTNP status of the
ndividuals included in our cohort. However, particular
mino acid changes within Nef proteins affecting their
unctions are not excluded from involvement in the out-
ome of HIV-1 infection. Interestingly, a recent report by
irchhoff et al. (1999) described that a large majority of
ef sequences from individuals infected by HIV-1 are
ull-length and that a link was determined between spe-
ific amino acid changes within Nef and the progression
tatus of the infected individuals. Further investigations
ill be necessary to gain a more precise understanding
f the different parameters involved in LTNP status and
n particular those involved in the subtle genetic changes
f the auxiliary genes.
MATERIALS AND METHODS
atients
Long-term nonprogressors were selected on the basis
f their asymptomatic status, stable CD4 cell counts, and
o anti-retroviral therapy (Candotti et al., 1999). They
ere infected for at least 8 years and their CD4 cell
ounts were stable during the past 3 years preceding
T AL.nclusion into the cohort. Late progressor controls were
nfected for at least 8 years without any symptoms and
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their CD4 cell counts had decreased at least 25% in the
past 3 years. When viral load data were obtained follow-
ing inclusion, individuals presenting viral loads greater
than 50,000 copies/ml were rapidly excluded from the
cohort, according to the rules of the French Ministry of
Health applied at this period (beginning in 1995).
Isolation of DNA from PBMC
Peripheral blood mononuclear cells were isolated
from heparinized blood using density-gradient centrifu-
gation on Ficoll–Hypaque (Pharmacia, Uppsala, Swe-
den). DNA was isolated from approximately 106 frozen
elleted PBMC (Candotti et al., 1999) according to the
oehringer Mannheim kit protocol (High Pure PCR tem-
late preparation kit). Less than 1 mg of DNA from PBMC
was used for PCR amplification.
Cells
HeLa and SupT1 or C8166 cells were grown and main-
tained in Dulbecco’s modified Eagle’s medium and RPMI
1640 medium, respectively, supplemented with 10% fetal
calf serum (FCS), antibiotics (penicillin and streptomy-
cin), and 2 mM glutamine. PBMC were obtained from
normal donor lymphopheresis samples which were ali-
quoted and stored in liquid nitrogen. After being thawed,
PBMC were grown in RPMI supplemented with 10% FCS
and phytohemagglutinin (PHA) for 3 days. Nonadherent
cells containing most of peripheral blood lymphocytes
were grown in RPMI supplemented by 10% FCS and 200
U/ml of interleukin-2 (IL2).
Transfections
Transfections were performed by the Fugen method as
recommended by the manufacturer (Roche Inc., Paris).
Briefly, HeLa cells were plated at 3.7 3 106 cells per
75-cm2 flask and grown overnight. Cells were incubated
ith 32 ml of Fugen and 10 mg of appropriate plasmid
NA for 48 h. Virus was quantified in cell-free superna-
ants by measuring reverse transcriptase (RT) activity as
reviously described (Rey et al., 1984).
nfection and virus propagation
Virus stocks were obtained 48 h after transfection of
eLa cells with appropriate viral DNA or from acutely
nfected SupT1 cells. SupT1 cells were infected by incu-
ating 2 3 106 cells with 1 ml of virus supernatant at
37°C by gentle shaking. After centrifugation at 800g for 5
min, cells were resuspended in culture medium at the
concentration of 5 3 105 cells/ml. Virus replication was
ssayed twice a week by determining the RT activity in
he cell-free supernatant. SupT1 virus stocks were fur-
vif GENE OF LONG-her titrated on C8166 to determine the infectious titer
xpressed as TCID50 per milliliter and were used in
v
1different dilutions to infect PBMC. On day 3 after PHA
stimulation, PBMC were infected with an equal m.o.i. of
wild-type or mutant viruses. HIV-1 productions in cell
cultures infected with serial fivefold dilutions of virus
stocks were assayed in triplicate.
Isolation of RNA from plasma virus and cDNA
synthesis
RNA from viral particles contained in 0.5 ml of plasma
was extracted with RNAXEL II kit following the manufac-
turer’s recommendation (Eurobio). Ethanol-precipitated
RNA was resuspended in diethyl-pyrocarbonate-treated
water and the cDNA synthesis was performed in 25 ml of
reverse transcriptase buffer (Promega) containing 100
mM DTT, 0.2 mM of antisense primer E2 used for PCR, 40
mM dATP, dCTP, dGTP, and TTP, 10 U of RT (AMV RT
Promega), and 20 U of RNasine (Promega) for 30 min at
40°C.
PCR amplification
A two-step PCR amplification, first with outer primers
E1 (59-CAAAATTTTCGGGTTTATTACAGGGAC, nt 4881 to
4907, sense) and E2 (59-CTGCTATGTTGACACCCAAT-
TCTG, nt 5788 to 5765, antisense) and then with inner
nested primers I1M13 (59-TGTAAAACGGCCAGTG-
GAAAGGTGAAGGGGCAGTAG, nt 4948 to 4968, sense)
and I2M13 (59-CAGGAAACAGCTATGACCTCTTAAGCTC-
CTCTAAAAGCTCTAGTG, nt 5631 to 5605, antisense),
was performed to obtain the vif gene sequence. The
nucleotides are numbered as in pNDK (Bouyac et al.,
1997; Spire et al., 1989) and the M13 sequences are
indicated in italics. PCR was performed with a 100-ml
eaction mixture containing PCR buffer (Stratagene), 40
mM dATP, dCTP, dGTP, and dTTP, 0.2 to 1 mM of each
outer primer pair, and 2.5 U of Pfu DNA polymerase.
Twofold end-point dilutions of DNA extracted from PBMC
or synthesized by in vitro RT reaction were used. The
reaction was carried out at 94°C for 30 s, 60°C for 1 min,
and 72°C for 1 min for 30 cycles. Five microliters of this
PCR product amplification was used for a nested PCR
according to the same protocol. The samples which
were further analyzed originated from the highest twofold
end-point dilutions which were positively amplified.
The amplified DNA products were purified by electro-
phoresis on a 1.5% low-melting agarose gel and ex-
tracted according to the DNA extraction kit protocol
(QIAEX II). The vif gene nucleotide sequences were de-
termined from both strands of amplified DNA with M13
primers by Genome Express (Grenoble, France).
vif gene cloning in recombined proviruses
(i) Construction of pNDKSmR with Unique SacII and
alI Sites. In order to clone the vif genes from different
177NONPROGRESSORSiruses, pNDK plasmid (Spire et al., 1989; Bouyac et al.,
997) carrying NDK provirus was modified by the addi-
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ene of NDK. A two-step recombinant PCR methodology
ith the following SacII and SalI primers, VIFK7SacII
59-GGTAGTACCGCGGAGAAAAGTAAAGATCATTAGGG,
nt 4994 to 5028, sense) and VIFK7SalI (59-CACTCTTAAG-
GTCGACTAAAAGCTCTAATGTCC, nt 5634 to 5602, anti-
sense), was used as previously described (Bouyac et al.,
1997). The nucleotide numbers are those of pNDK
(Bouyac et al., 1997; Spire et al., 1989), the SacII and SalI
sites are indicated in italics and the mutated nucleotides
are underlined. The pNDKSacIISalI plasmid keeps the
open reading frames surrounding vif of HIV-1 intact. The
changes of the three nucleotides within the inserted SalI
and SacII sites have no amino acid change in the IN
domain of Pol and only two amino acid changes in Vpr, E
to V at position 24 and E to D at position 25. Then,
pNDKSmR was constructed to eliminate the parental vif
ene from pNDK. This construction was obtained by
eplacing the vif gene of NDK between the SacII and SalI
ites of pNDKSacIISalI by a DNA coding for the resis-
ance to streptomycine, SmR (Golden and Wiest, 1988).
(ii) YU2 vif Gene Cloning. Following the amplification
of YU2 DNA by the outer primers E1 and E2 (see above),
first-step PCR products were amplified by the VIFK7SacII
and VIFK7SalI primers surrounding the vif gene of NDK
nd highly conserved in YU2 provirus. This second PCR
roduct, which was naturally blunt-ended with Pfu DNA
olymerase, was cloned into the pCR-Blunt vector (Zero
lunt PCR cloning kit, Invitrogen). After selection and
ropagation of appropriate plasmids in Top10 or XL1
lue Escherichia coli bacteria, recombinant DNA was
urified with the QIAEX II DNA extraction kit from Qiagen.
fter SalI and SacII (Biolabs) digestion, the YU2 vif gene
was extracted on a low-melting agarose gel and cloned
into the plasmid pNDKSmR.
The same strategy was used for the YU2 vif gene
utant R132S. This mutant was obtained by two-step
CR mutagenesis on the YU2 vif gene with the primers
IFK7SacII and YU132B (59-GCTTGATATTCACAACTAG-
GACTAACTC, nt 5448 to 5421, antisense) and with the
primers YU132A (59-GAGTTAGTCCTAGTTGTGAATAT-
CAAAGC, nt 5421 to 5448, sense) and VIFK7SalI. The
YU-2 nucleotide coordinates were those previously de-
scribed (Li et al., 1992) and the mutated G to T sense
ucleotide is underlined in the mutagenesis primers. The
U-2 vif gene with the mutation T159I has been gener-
ted with the following mutagenesis primers: YU1592
(59-CAAAGGTGGCTTTATCTTTTTTGGTG, nt 5527 to
5502, antisense) and YU1591 (59-CACCAAAAAAGATA-
AAGCCACCTTTG, nt 5502 to 5527, sense). The reactions
were carried out at 90°C for 30 s, 55°C for 45 s, and 72°C
for 50 s for 30 cycles. The two PCR products were
purified as previously described and mixed at an
equimolar ratio for a second PCR with the primers
178 HASSAVIFK7SacII and VIFK7SalI carried out at 90°C for 30 s,
60°C for 45 s, and 72°C for 1.5 min for 30 cycles.Phylogenetic analysis of HIV-1 vif sequences and
statistical testing
The nucleotide sequences of the vif genes (576 bp)
from the 42 LTNP and the 8 late progressors were trans-
lated to corresponding amino acid sequences (192
amino acids). Zhang’s sequences (Zhang et al., 1997b)
were obtained from the author and those of Sova et al.
(1995) were obtained from GenBank. Alignments were
performed with the ClustalW program (Thompson et al.,
994). Phylogenetic trees of nucleotide and amino acid
equences were constructed by the neighbor joining
ethod available in ClustalW (Thompson et al., 1994).
Amino acids localized at certain positions and asso-
ciated with specific groups of individuals were deter-
mined with VESPA, according to Korber and Myers
(Korber and Myers, 1992). Statistical significance of the
distribution of amino acid signatures among different
groups of individuals was assessed by Student t test.
Significant correlations (P , 0.05) between amino acid
signatures and viral loads were assessed with Statview
using the Mann–Whitney and Kruskall–Wallis tests.
Nucleotide sequence accession numbers
The major nucleotide sequences that we obtained for
the vif genes from each patient have been submitted to
GenBank under Accession Nos. AF143097 to AF143146.
APPENDIX
The French ALT Study Group is composed of the
presenting authors together with V. Calvez, C. Tareau, C.
Robert, and J.-M. Huraux, Laboratoire de Virologie, Hoˆ-
pital Pitie´-Salpeˆtrie`re, Paris; D. Costagliola, A. Goubar,
and L. Marrero, INSERM SC4, Faculte´ de Me´decine
Saint-Antoine, Paris; O. Bonduelle, F. Hadida, M. Magier-
owska, I. Theodorou, and P. Debre´, Laboratoire
d’Immunologie Cellulaire et Tissulaire, CNRS URA 625,
Hoˆpital Pitie´-Salpetrie`re, Paris; C. Rouzioux and N. Ngo-
Giang-Huong, Laboratoire de Virologie, Hoˆpital Necker-
Enfants-Malades, Paris; J.-P. Clauvel and J.-M. Bouley,
Laboratoire d’Immuno-He´matologie, Hoˆpital Saint-Louis,
Paris; D. Sicard and S. Chaput, Me´decine Interne, Hoˆpital
Cochin, Paris; and G. Sanchez and I. Hirsch, INSERM
U372, Campus de Luminy, Marseille, France.
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T AL.Note added in proof. During the correction of this manuscript, Alex-
ander et al. (L. Alexander, E. Weiskopf, T. C. Greenough, N. C. Gaddis,
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R. C. Desrosiers, J. Virol. 74, 4361–4376, 2000) reported the vif se-
uences of eight LTNP and six of them have a residue other than Arg
n position 132 including four individuals with Ser.
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